论文部分内容阅读
目的确定乳腺癌患者血清中血管生长因子及生长抑素在治疗后随访中的意义,初步建立乳腺癌治疗后新的随访指标。方法采集我科治疗的59例女性乳腺癌患者血清样本,其中未手术者14例,根治术后初治患者21例,病情进展转移及复发者19例,治疗后病情稳定超过1年者5例。ELISA法测定血清中血管内皮生长因子(VEGF)以及生长抑素(SS)的含量,观察乳腺癌治疗后血清中血管生长因子以及生长抑素在乳腺癌中的表达。结果乳腺癌患者血清VEGF及SS水平在治疗后均明显下降(P<0.05)。它们在出现复发转移的患者中明显升高(P<0.05)。结论血清VEGF及SS随着乳腺癌患者病情进展而升高,可联合检测作为患者随访的指标。
Objective To determine the significance of serum VEGF and somatostatin in follow-up of patients with breast cancer and to establish a new follow-up index after breast cancer treatment. Methods Serum samples from 59 women with breast cancer who were treated by our department were collected. Among them, 14 were untreated, 21 were untreated, 19 were metastatic and relapsed, and 5 were stable after more than one year after treatment . Serum levels of vascular endothelial growth factor (VEGF) and somatostatin (SS) were measured by ELISA. The expression of serum vascular growth factor and somatostatin in breast cancer tissues after breast cancer treatment was observed. Results Serum levels of VEGF and SS in patients with breast cancer were significantly decreased after treatment (P <0.05). They were significantly higher in patients with recurrence and metastasis (P <0.05). Conclusions Serum VEGF and SS are increased with the progress of breast cancer patients. They may be combined as a marker for follow-up of patients.